Neuroendocrine Tumors (NETs & PNETs)

Neuroendocrine tumors (NETs) arise from the diffuse neuroendocrine system and range from indolent carcinoids to aggressive neuroendocrine carcinomas. Key therapies include somatostatin analogs (octreotide LAR, lanreotide), Lu-177 dotatate PRRT for SSTR-positive midgut NETs (NETTER-1), everolimus and sunitinib for progressive pancreatic NETs (pNETs), and CAPTEM (capecitabine + temozolomide) as the preferred oral cytotoxic for pNETs — MGMT promoter methylation is the key biomarker for CAPTEM selection (ORR ~33% methylated vs. ~14% unmethylated; ECOG-ACRIN E2211).

Approved drugs, investigational agents, and relevant clinical trials for this disease area.

Approved Drugs for Neuroendocrine Tumors (NETs & PNETs)

• Everolimus (Afinitor) — Other
• Sunitinib (Sutent) — Tyrosine Kinase Inhibitor
• Capecitabine (Xeloda) — Antimetabolite
• Temozolomide (Temodar) — Alkylating Agent
• Streptozocin (Zanosar) — Alkylating Agent